Intestinal Toxicity in Rats Following Administration of Cdk4/6 Inhibitors Is Independent of Primary Pharmacology

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-0734
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Treating ER+ Breast Cancer With CDK4/6 Inhibitors

Cancer Discovery
Oncology
2017English

CDK4/6 Inhibitors: Promising Opportunities Beyond Breast Cancer

Cancer Discovery
Oncology
2016English

Loss of FAT1 Drives Resistance to CDK4/6 Inhibitors in Breast Cancer

Cancer Discovery
Oncology
2018English

CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2 + Breast Cancer

Cancer Cell
Cancer ResearchOncologyCell Biology
2016English

Inhibitors Targeting CDK4/6, PARP and PI3K in Breast Cancer: A Review

Therapeutic Advances in Medical Oncology
Oncology
2018English

A Novel Tankyrase Inhibitor, MSC2504877, Enhances the Effects of Clinical CDK4/6 Inhibitors

Scientific Reports
Multidisciplinary
2019English

Effects Following the Intestinal Administration of (Iletin) Insulin

American Journal of Physiology-Legacy Content
1923English

Cdk4/6 Inhibitors and Overall Survival: Power of First-Line Trials in Metastatic Breast Cancer

npj Breast Cancer
OncologyRadiologyNuclear MedicinePharmacologyImaging
2018English

Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer

ACS Chemical Biology
BiochemistryMedicineMolecular Medicine
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy